Clinical trials
Glomerulonephritis clinical trials
Below are recruiting glomerulonephritis clinical trials, each written for real people, not researchers. We’re tracking 27 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT07746180RecruitingPhase 2
Obinutuzumab and low-dose steroids for new kidney disease
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
BeijingAges 18 years+ - NCT04183101RecruitingPhase 2
Aliskiren vs enalapril for C3 kidney inflammation
This trial tests whether aliskiren works better or as well as enalapril to treat C3 glomerulopathy/dense deposit disease confirmed by a kidney biopsy. It may help by improving kidney outcomes in people with this specific kidney condition.
GothenburgAges 6 years+ - NCT06858319RecruitingPhase 3
Long-term study of zigakibart for IgA nephropathy
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Denver, ColoradoAges 18–100 - NCT06295770RecruitingPhase 2
Obinutuzumab for fibrillary glomerulonephritis
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
Rochester, MinnesotaAges 18 years+ - NCT05946564RecruitingPhase 3
Pioglitazone to protect kidney function in ANCA vasculitis
This Phase 3 trial tests whether pioglitazone can help protect kidney function in people with newly diagnosed or relapsing ANCA-associated vasculitis that is actively affecting the kidneys. It aims to improve “renal tolerance,” meaning your kidneys may be better able to tolerate the disease and treatment.
AmiensAges 18–80 - NCT04663204RecruitingPhase 2
Sparsentan study for IgA kidney disease in adults
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
Cambridge, EnglandAges 18 years+ - NCT03929887Recruiting
Kidney biopsy patients join a kidney tissue research bank
This study builds a kidney tissue “library” to help researchers analyze kidney disease in newer ways. It may help by improving how glomerular (kidney filter) diseases are understood over time, using samples from people who already had a biopsy.
ChuncheonAges Any age - NCT05510323RecruitingPhase 3
Immunosuppressive treatment for IgA kidney disease in stage 3–4
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
Xi'anAges 18 years+ - NCT07851220RecruitingPhase 3
Study of inebilizumab for primary membranous nephropathy
This study tests a new medicine called inebilizumab for people with primary membranous nephropathy, a kidney disease. The medicine may help reduce protein in the urine and protect kidney function.
Los Angeles, CaliforniaAges 18–79 - NCT07746895RecruitingPhase 4
Study of pegcetacoplan for C3G or IC-MPGN kidney disease
This study looks at how well pegcetacoplan works and how safe it is for people with two rare kidney diseases, called C3G and IC-MPGN. It will help doctors understand how the medicine helps patients in real life, outside of a strict clinical trial.
KingswoodAges Any age - NCT05791162Recruiting
Looking at immune cell ratios in IgA kidney disease
This study looks at how certain immune cells in blood relate to IgA nephropathy, a kidney condition. It may help doctors understand which patients are likely to do better and guide future care.
BesançonAges 18 years+ - NCT07585981Recruiting
Budesonide capsules for IgA kidney disease
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
BeijingAges 18 years+ - NCT07330362Recruiting
AI to help diagnose kidney disease from biopsy
This trial tests an artificial intelligence system that helps doctors analyze kidney tissue samples. If you have chronic kidney disease and need a biopsy, this study will see if the AI can improve diagnosis.
Guangzhou, GuangdongAges 15–79 - NCT04662723RecruitingPhase 4
Personalized treatment for IgA kidney disease
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
Bari, BAAges 18 years+ - NCT01802034Recruiting
Study kidney samples to understand autoimmune, inflammatory, and diabetic disease
This trial collects and studies kidney tissue samples to better understand what drives kidney problems linked to autoimmune, inflammation, and diabetes. Your participation may help researchers develop better ways to diagnose and treat these conditions.
New York, New YorkAges 18 years+ - NCT07203404RecruitingEarly Phase 1
A study of a universal CAR-T cell therapy for autoimmune diseases
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT06889948RecruitingPhase 2
Daratumumab for kidney disease caused by abnormal proteins
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
HelsinkiAges 18 years+ - NCT06676384RecruitingPhase 4
Testing additional drugs for IgA nephropathy in South Asian patients
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Nadiād, GujaratAges 18–65 - NCT06209736RecruitingPhase 2
Study of OMS906 for C3G and ICGN kidney diseases
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
KaunasAges 18–99 - NCT06797518RecruitingPhase 2
Testing iptacopan for IgA nephropathy kidney changes
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
Birmingham, AlabamaAges 18–99 - NCT06500702RecruitingPhase 2
Study of three drugs for FSGS or minimal change disease
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
Birmingham, AlabamaAges 16–75 - NCT06047171RecruitingPhase 2
Testing ALE.F02 for new kidney inflammation from vasculitis
This trial tests a new medicine called ALE.F02 for people newly diagnosed with a type of kidney inflammation called rapidly progressive glomerulonephritis (RPGN) caused by ANCA vasculitis. The goal is to see if it can help rescue kidney function.
PragueAges 18 years+
Hear when a new Glomerulonephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glomerulonephritis?
- Yes. Clin2 currently lists 27 recruiting glomerulonephritis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glomerulonephritis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glomerulonephritis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.